Two new medications for active Takayasu's arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with Takayasu's arteritis (a disease that causes swelling in your large blood vessels).
- Your disease must be active even though you are currently taking steroids and another medication that suppresses your immune system (but you haven't taken a JAK inhibitor or IL-17 inhibitor).
- If you have an infection like hepatitis B, C, or tuberculosis, you may need treatment for it before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called deucravacitinib (which is already used for psoriasis) to see if it can calm inflammation in Takayasu's arteritis. If you have active disease despite current treatment, this may offer a new option to help control symptoms and prevent damage.
This study tests a new ultrasound scoring system to monitor disease activity in people with Takayasu arteritis. It aims to see if ultrasound can reliably track the disease, which might help guide treatment decisions.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
This study looks at people with Takayasu's arteritis that also affects the lungs' blood vessels. Researchers want to understand the disease's behavior and outcomes over time.
Hear when a new Takayasu Arteritis (TAK) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.